Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac059 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Takeshi Mochizuki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Kamagaya General Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: Osteoporosis, Bone Density Conservation Agents, Arthritis, Rheumatoid, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Objectives
To investigate the effect of romosozumab versus denosumab treatment on bone mineral density (BMD), disease activity, and joint damage in patients with rheumatoid arthritis and severe osteoporosis.
Methods
Fifty-one postmenopausal women were enrolled and randomized equally into two groups to receive either romosozumab or the denosumab. Changes (Δ) in the BMD (at lumbar spine, total hip, and femoral neck), disease activity score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR), and van der Heijde-modified Total Sharp Score (TSS) from baseline to 12 months after treatment were evaluated.
Results
The ΔBMD at 12 months in the romosozumab and denosumab groups were 10.2 ± 5.6% and 5.0 ± 3.1% (p = .002) for the lumbar spine, 3.7 ± 4.9% and 3.5 ± 3.0% (p = .902) for the total hip, and 3.6 ± 4.7% and 3.2 ± 4.9% (p = .817) for the femoral neck, respectively. The ΔDAS28-ESR and ΔTSS at 12 months did not differ between these two groups.
Conclusions
Our results suggest that romosozumab treatment was more effective in increasing the BMD at the lumbar spine than denosumab and may be selected for patients who require a significant increase in the lumbar spine BMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Kamagaya General Hospital, Chiba, Japan.
- Department of Orthopaedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
- Division of Multidisciplinary Management of Rheumatic Diseases, Tokyo Women's Medical University, Tokyo, Japan.
Zitieren
APA
Mochizuki, T., Yano, K., Ikari, K., Hiroshima, R., & Okazaki, K. (2023). Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study. Modern Rheumatology. https://doi.org/10.1093/mr/roac059
Vancouver
Mochizuki T, Yano K, Ikari K, Hiroshima R, Okazaki K. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study. Modern Rheumatology. 2023. doi:10.1093/mr/roac059
BibTeX
@article{Mochizuki2023,
author = {Mochizuki, Takeshi and Yano, Koichiro and Ikari, Katsunori and Hiroshima, Ryo and Okazaki, Ken},
title = {Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac059}
}
EUVIMED